Erbitux 5mg/ml Injection 20 ml
₹17425*
MRP ₹21250
18% off
₹18062*
MRP ₹21250
15% CB
₹3188 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Erbitux 5mg/ml Injection 20 ml belongs to a class of monoclonal antibodies. It is used with or without radiation therapy to treat various cancer conditions, such as metastatic cancer of the large intestine and squamous cell cancer (a certain type of head and neck cancer). Cancer is a genetic change in which the body's cells divide uncontrollably and spread into surrounding tissues.
Erbitux 5mg/ml Injection 20 ml contains Cetuximab, which works by slowing or stopping the growth of cancer cells. As a result, it prevents the cancer from spreading.
Erbitux 5mg/ml Injection 20 ml will be administered by a qualified healthcare professional who is experienced in the administration of chemotherapeutic agents. The most common side effects are inflammation of the lining of the intestine, mouth, and nose, nose bleeding, headache, tiredness, irritation and redness of the eye, diarrhoea, feeling sick, vomiting, loss of appetite, and weight loss. Talk to your doctor if any of these side effects persist or worsen.
It is recommended not to use if you are allergic to any ingredient in Erbitux 5mg/ml Injection 20 ml. Erbitux 5mg/ml Injection 20 ml may cause foetal harm when administered to a pregnant woman. It is critical not to become pregnant while undergoing therapy and for several months after the treatment. Before beginning treatment, discuss effective contraception with your healthcare professional. Inform them immediately if you or your partner becomes pregnant while undergoing therapy. Do not breastfeed your baby while on treatment with Cetuximab and for two months after the last dose. Alcohol should be avoided during treatment with this medicine. Drive only if you are alert, as the Erbitux 5mg/ml Injection 20 ml may cause you to feel sick or tired.
If you have head and neck cancer and are treated with radiation therapy with cetuximab, you may be at an elevated risk of cardiopulmonary arrest (when the heart stops beating and respiration stops) and sudden death during or after treatment. Inform your doctor if you have or have ever had coronary artery disease (a condition in which the blood vessels of the heart narrow or become clogged by fat or cholesterol deposits); heart failure (a condition in which the heart is unable to pump enough blood to the rest of the body); irregular heartbeat; other heart disease; or lower than normal levels of magnesium, potassium, or calcium in your blood.
Erbitux 5mg/ml Injection 20 ml is a monoclonal antibody. It is used alone or in combination with other anticancer medications to treat various cancer diseases, including metastatic cancer of the large intestine and squamous cell cancer (a form of head and neck cancer). Cetuximab is present in Erbitux 5mg/ml Injection 20 ml and works by slowing or preventing the growth of cancer cells. As a result, it inhibits the cancer from spreading.
Before taking Erbitux 5mg/ml Injection 20 ml, inform your doctor about your medical history and ongoing therapies to rule out potential adverse effects or interactions. It's crucial to take your medication as directed. The dosage of this medicine is based on your condition. Your doctor may adjust your dose during therapy based on the treatment results. Consult a doctor immediately if you suffer any symptoms, especially if you also have a cough or fever, such as the onset or worsening of breathing problems. If therapy needs to be stopped, your doctor will make that decision. Erbitux 5mg/ml Injection 20 ml is recommended not to be used in pregnant women or nursing mothers; if you become pregnant while on treatment with Cetuximab, tell your doctor right away.
Drug-Drug Interactions: Erbitux 5mg/ml Injection 20 ml may interact with certain medications used to treat actinic keratoses (e.g. aminolevulinic acid) and anti-cancer medications (e.g. thalidomide)
Drug-Food Interactions: Avoid the consumption of alcoholic beverages.
Drug-Disease Interactions: Erbitux 5mg/ml Injection 20 ml may interact with disease conditions, including hypocalcemia (low calcium levels), electrolyte abnormalities, hypokalemia (low potassium levels), magnesium imbalance, hypersensitivity reactions to drugs, ocular infection (eye infection), pulmonary impairment, fever, and cardiovascular diseases such as arrhythmias (irregular heartbeat), congestive heart failure and qt prolongation.
Do not skip any scheduled doctor or lab appointments.
Cancer: Cancer is a genetic change in which the body's cells divide uncontrollably and spread into surrounding tissues. There are two types of cancer: benign (localized) and metastatic (spread to the whole body). Types of cancer include blood, lung, breast, etc. Cancer growth can be prevented by chemotherapy, radiation, and stem cell therapy.
Metastatic cancer: Metastasis occurs when cancer cells move from the colon to other organs. This is also known as stage IV colon cancer or advanced colon cancer.
Head and Neck Cancer: Cancers of the larynx, throat, lips, mouth, nose, and salivary glands are among the head and neck cancers. Human papillomavirus (HPV) infection, excessive alcohol consumption, and tobacco use all raise the risk of head and neck cancer.
Country of origin
Manufacturer/Marketer address
Keep Refrigerated. Do not freeze.Prepaid payment required.
Alcohol
Unsafe
Avoid alcohol consumption while on treatment with Erbitux 5mg/ml Injection 20 ml as it may cause serious side effects.
Pregnancy
Unsafe
Erbitux 5mg/ml Injection 20 ml is not recommended for use during pregnancy. So, inform your doctor if you are pregnant or suspect pregnancy. You or your partner must use a reliable form of contraception to prevent pregnancy while on treatment with Erbitux 5mg/ml Injection 20 ml.
Breast Feeding
Unsafe
Do not breastfeed your baby when you are being treated with Erbitux 5mg/ml Injection 20 ml and for two months after the last dose.
Driving
Caution
Drive only if alert, as the Erbitux 5mg/ml Injection 20 ml may cause feeling sick or tiredness.
Liver
Caution
If you have a pre-existing or a history of liver disease, inform your doctor before receiving Erbitux 5mg/ml Injection 20 ml. Your doctor will weigh the benefits and potential risks before prescribing this medicine.
Kidney
Caution
If you have a pre-existing or a history of kidney disease, inform your doctor before taking Erbitux 5mg/ml Injection 20 ml. Your doctor may titrate the dose if required based on your condition.
Children
Safe if prescribed
Erbitux 5mg/ml Injection 20 ml can be used to treat certain cancers in children. Please consult your doctor for more information.
Product Substitutes
We provide you with authentic, trustworthy and relevant information